Literature DB >> 18028412

Molecular background of EPM1-Unverricht-Lundborg disease.

Tarja Joensuu1, Anna-Elina Lehesjoki, Outi Kopra.   

Abstract

Unverricht-Lundborg disease (EPM1) is an autosomal recessively inherited neurodegenerative disorder and the most common single cause of progressive myoclonus epilepsy worldwide. Mutations in the gene encoding cystatin B (CSTB), a cysteine protease inhibitor, are responsible for the primary defect underlying EPM1. Here, progress toward understanding the molecular mechanisms in EPM1 is reviewed. We summarize the current knowledge about the CSTB gene and mutations as well as the cellular biology of the CSTB protein with emphasis on data emerging from analysis of EPM1 patients. We shed light on the disease mechanisms of EPM1 based on characterization of the CSTB-deficient mouse model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18028412     DOI: 10.1111/j.1528-1167.2007.01422.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  26 in total

Review 1.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

2.  Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

Authors:  Dun-Sheng Yang; Philip Stavrides; Panaiyur S Mohan; Susmita Kaushik; Asok Kumar; Masuo Ohno; Stephen D Schmidt; Daniel Wesson; Urmi Bandyopadhyay; Ying Jiang; Monika Pawlik; Corrinne M Peterhoff; Austin J Yang; Donald A Wilson; Peter St George-Hyslop; David Westaway; Paul M Mathews; Efrat Levy; Ana M Cuervo; Ralph A Nixon
Journal:  Brain       Date:  2011-01       Impact factor: 13.501

3.  Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1.

Authors:  Maria K Lehtinen; Saara Tegelberg; Hyman Schipper; Haixiang Su; Hillel Zukor; Otto Manninen; Outi Kopra; Tarja Joensuu; Paula Hakala; Azad Bonni; Anna-Elina Lehesjoki
Journal:  J Neurosci       Date:  2009-05-06       Impact factor: 6.167

4.  Interaction between oligomers of stefin B and amyloid-beta in vitro and in cells.

Authors:  Katja Skerget; Ajda Taler-Vercic; Andrej Bavdek; Vesna Hodnik; Slavko Ceru; Magda Tusek-Znidaric; Tiina Kumm; Didier Pitsi; Marusa Pompe-Novak; Peep Palumaa; Salvador Soriano; Natasa Kopitar-Jerala; Vito Turk; Gregor Anderluh; Eva Zerovnik
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

Review 5.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 6.  Genetics of epilepsy and relevance to current practice.

Authors:  Roberto Michelucci; Elena Pasini; Patrizia Riguzzi; Lilia Volpi; Emanuela Dazzo; Carlo Nobile
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

7.  Severe neurodegeneration, progressive cerebral volume loss and diffuse hypomyelination associated with a homozygous frameshift mutation in CSTB.

Authors:  Alan O'Brien; Christian R Marshall; Susan Blaser; Peter N Ray; Grace Yoon
Journal:  Eur J Hum Genet       Date:  2017-04-05       Impact factor: 4.246

8.  A role for stefin B (cystatin B) in inflammation and endotoxemia.

Authors:  Katarina Maher; Barbara Jerič Kokelj; Miha Butinar; Georgy Mikhaylov; Mateja Manček-Keber; Veronika Stoka; Olga Vasiljeva; Boris Turk; Sergei A Grigoryev; Nataša Kopitar-Jerala
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

9.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis.

Authors:  Remington L Nevin
Journal:  Malar J       Date:  2009-08-05       Impact factor: 2.979

10.  Secondary biogenic amine deficiencies: genetic etiology, therapeutic interventions, and clinical effects.

Authors:  Maja Tarailo-Graovac; Gabriella A Horvath; Clara D van Karnebeek; Ingrid Blydt-Hansen; Allison M Matthews; Vladimir Avramovic; Magda Price; Britt Drogemoller; Casper Shyr; Jessica Lee; Jill Mwenifumbo; Aisha Ghani; Sylvia Stockler; Jan M Friedman; Anna Lehman; Colin J Ross; Wyeth W Wasserman
Journal:  Neurogenetics       Date:  2021-07-02       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.